[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vaxcyte Inc (PCVX)

Vaxcyte Inc (PCVX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,654,538
  • Shares Outstanding, K 144,398
  • Annual Sales, $ 0 K
  • Annual Income, $ -766,630 K
  • EBIT $ -924 M
  • EBITDA $ -913 M
  • 60-Month Beta 1.30
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.48

Options Overview Details

View History
  • Implied Volatility 74.82% (-1.83%)
  • Historical Volatility 47.59%
  • IV Percentile 77%
  • IV Rank 64.98%
  • IV High 90.62% on 11/04/25
  • IV Low 45.50% on 01/16/26
  • Expected Move (DTE 5) 2.25 (4.25%)
  • Put/Call Vol Ratio 2.24
  • Today's Volume 9,895
  • Volume Avg (30-Day) 900
  • Put/Call OI Ratio 2.26
  • Today's Open Interest 55,273
  • Open Int (30-Day) 49,296
  • Expected Range 50.76 to 55.26

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.79
  • Number of Estimates 3
  • High Estimate $-1.47
  • Low Estimate $-2.19
  • Prior Year $-1.22
  • Growth Rate Est. (year over year) -46.72%

Price Performance

See More
Period Period Low Period High Performance
1-Month
48.49 +9.32%
on 05/07/26
63.31 -16.27%
on 04/17/26
-7.09 (-11.80%)
since 04/08/26
3-Month
48.49 +9.32%
on 05/07/26
65.00 -18.45%
on 02/25/26
-3.14 (-5.59%)
since 02/06/26
52-Week
28.64 +85.09%
on 05/14/25
65.00 -18.45%
on 02/25/26
+21.56 (+68.55%)
since 05/08/25

Most Recent Stories

More News
Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update

Enrollment Now Completed for OPUS-1, OPUS-2 and OPUS-3 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults Topline Safety, Tolerability and...

PCVX : 53.01 (+2.97%)
Vaxcyte Approaches Its First Earnings Call Since Analysts Stopped Raising Targets

Barchart Research What to Expect from PCVX Earnings PCVX Generated May 5, 2026 Current Price $55.69 EPS Estimate $$-1.86 Consensus Rating Strong Buy Average Move 4.17% Vaxcyte Approaches Its First Earnings...

PCVX : 53.01 (+2.97%)
Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference

SAN CARLOS, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside...

PCVX : 53.01 (+2.97%)
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

OPUS-1 Phase 3 Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines (PCVs) Through Head-to-Head Safety, Tolerability and Immunogenicity Comparisons of VAX-31 with Capvaxive...

PCVX : 53.01 (+2.97%)
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate

Based on the Strength of Unprecedented Results from the Positive Phase 1/2 Study in Adults Aged 50 and Older, Vaxcyte Advanced VAX-31 High Dose into Comprehensive Phase 3 Adult Program; Topline Data from...

PCVX : 53.01 (+2.97%)
Love A Little Risk? Wall Street Sees Massive Upside in Vaxcyte Stock.

For growth-focused biotech investors, Vaxcyte is no longer just a science story.

PCVX : 53.01 (+2.97%)
STRO : 40.24 (+1.03%)
LZAGY : 62.5800 (+0.79%)
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Comprehensive VAX-31 Adult Phase 3 Clinical Program, Finalized in Consultation and Alignment with FDA, Advances with Three Phase 3 Studies Underway to Support Planned BLA Submission Topline Safety,...

PCVX : 53.01 (+2.97%)
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines

Company Expects to Report Topline Data from OPUS-3 Trial and OPUS-2 Phase 3 Trial Evaluating Concomitant Administration of VAX-31 and a Seasonal Influenza Vaccine in First Half of 2027  OPUS-1,...

PCVX : 53.01 (+2.97%)
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026

SAN CARLOS, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today that it will report financial results for the fourth quarter...

PCVX : 53.01 (+2.97%)
Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit

SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside...

PCVX : 53.01 (+2.97%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Vaxcyte Inc.is a biopharmaceutical company develops vaccines for infectious diseases. It offers conjugate, pneumococcal conjugate and complex antigen-based vaccines. Vaxcyte Inc.is based in Foster City, California.

See More

Key Turning Points

3rd Resistance Point 56.56
2nd Resistance Point 54.98
1st Resistance Point 53.99
Last Price 53.01
1st Support Level 51.42
2nd Support Level 49.84
3rd Support Level 48.85

See More

52-Week High 65.00
Last Price 53.01
Fibonacci 61.8% 51.11
Fibonacci 50% 46.82
Fibonacci 38.2% 42.53
52-Week Low 28.64

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.